1. Home
  2. HWKN vs EWTX Comparison

HWKN vs EWTX Comparison

Compare HWKN & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hawkins Inc.

HWKN

Hawkins Inc.

HOLD

Current Price

$132.72

Market Cap

3.4B

ML Signal

HOLD

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

HOLD

Current Price

$44.34

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HWKN
EWTX
Founded
1938
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.7B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
HWKN
EWTX
Price
$132.72
$44.34
Analyst Decision
Buy
Buy
Analyst Count
2
6
Target Price
$200.00
$39.00
AVG Volume (30 Days)
172.3K
1.6M
Earning Date
05-13-2026
05-07-2026
Dividend Yield
0.46%
N/A
EPS Growth
N/A
N/A
EPS
3.91
N/A
Revenue
$1,083,696,000.00
N/A
Revenue This Year
$12.37
N/A
Revenue Next Year
$6.30
N/A
P/E Ratio
$34.02
N/A
Revenue Growth
11.21
N/A
52 Week Low
$117.98
$12.31
52 Week High
$186.15
$48.40

Technical Indicators

Market Signals
Indicator
HWKN
EWTX
Relative Strength Index (RSI) 29.04 62.42
Support Level $128.75 $29.03
Resistance Level $156.86 N/A
Average True Range (ATR) 7.15 2.71
MACD -2.28 0.62
Stochastic Oscillator 6.18 69.29

Price Performance

Historical Comparison
HWKN
EWTX

About HWKN Hawkins Inc.

Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The industrial segment, which generates the majority of revenue, sells private label bleach, caustic soda, sulfuric acid, hydrochloric acid, phosphoric acid, potassium hydroxide, and aqua ammonia. The water treatment segment sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. The health and nutrition segment sells ingredients to food, beverage, personal care, and dietary supplement producers. The majority of revenue is gained from Water Treatment.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Share on Social Networks: